MAPS is currently seeking $9 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA, with $897,735 already raised and roughly $8.1 million still to go. We have completed key negotiations with EMA, and we will have an ever more precise estimate of timetables and costs for Phase 3 EMA trials in mid-2019 after completion of our negotiations with each country in the EMA in which we will have a Phase 3 site, and with each site.
In September 2018, MAPS raised nearly $100,000 in new donations and pledges from 638 supporters.
We extend a special thanks to those who so generously supported MAPS last month:
General Support:
- Threshold Foundation ($23,000)
- Mary & Robert Haft Foundation ($20,000)
- Anonymous ($5,000)
- Andrew Ryan ($2,500)
- Mack Fuhrer ($2,500)
- Anonymous ($2,229)
- Oril Rinat ($1,800)
- Grant Leonard ($1,100)
- Latane Temple Keeler ($1,000)
- Anonymous ($1,000)
- Ethan Devine ($1,000)
Phase 3 MDMA/PTSD U.S.:
- Highfield Foundation ($2,500)
Phase 3 GMP Drug:
- Lora Sasiela ($1,000)
Zendo Project:
- George Goldsmith ($5,000)
- Ben Williamson ($1,000)
- Jared Luxenberg ($1,000)
- Ethan Devine ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
Learn how to include MAPS in your will or estate plans.
Learn more about hosting a Global Psychedelic Dinner to fundraise for MAPS.
